Corona Remedies Bhayla facility commences additional commercial production of medicines
Written By : Ruchika Sharma
Published On 2025-12-29 05:00 GMT | Update On 2025-12-29 05:00 GMT
Advertisement
Ahmedabad: Corona Remedies has announced that the Company has successfully commenced the additional commercial production of tablet(s) / capsule(s) at the Bhayla manufacturing facility of the Company.
As on March 31, 2025, the Facility has an installed capacity of 852.80 million with the available capacity of 600 million and actual production of 561.49 million which is equivalent to capacity utilization of 93.58%.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.